Compare ASTRAZENECA PHARMA with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PIRAMAL ENTERPRISES ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 134.3 -36.5 - View Chart
P/BV x 37.7 1.2 3,063.0% View Chart
Dividend Yield % 0.0 1.9 -  

Financials

 ASTRAZENECA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-19
ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2783,303 38.7%   
Low Rs8831,797 49.1%   
Sales per share (Unadj.) Rs228.4716.5 31.9%  
Earnings per share (Unadj.) Rs10.479.7 13.0%  
Cash flow per share (Unadj.) Rs16.3107.9 15.1%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.81,477.5 6.7%  
Shares outstanding (eoy) m25.00184.45 13.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.73.6 132.9%   
Avg P/E ratio x104.232.0 325.8%  
P/CF ratio (eoy) x66.423.6 281.2%  
Price / Book Value ratio x10.91.7 633.8%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m27,008470,292 5.7%   
No. of employees `0001.47.8 17.3%   
Total wages/salary Rs m1,53522,504 6.8%   
Avg. sales/employee Rs Th4,210.916,899.4 24.9%   
Avg. wages/employee Rs Th1,132.22,877.7 39.3%   
Avg. net profit/employee Rs Th191.11,879.9 10.2%   
INCOME DATA
Net Sales Rs m5,710132,153 4.3%  
Other income Rs m1233,128 3.9%   
Total revenues Rs m5,833135,281 4.3%   
Gross profit Rs m46366,290 0.7%  
Depreciation Rs m1475,202 2.8%   
Interest Rs m044,097 0.0%   
Profit before tax Rs m43820,119 2.2%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1798,611 2.1%   
Profit after tax Rs m25914,701 1.8%  
Gross profit margin %8.150.2 16.2%  
Effective tax rate %40.842.8 95.4%   
Net profit margin %4.511.1 40.8%  
BALANCE SHEET DATA
Current assets Rs m3,209122,742 2.6%   
Current liabilities Rs m2,070310,810 0.7%   
Net working cap to sales %20.0-142.3 -14.0%  
Current ratio x1.60.4 392.7%  
Inventory Days Days7223 313.6%  
Debtors Days Days3539 89.9%  
Net fixed assets Rs m790116,904 0.7%   
Share capital Rs m50369 13.6%   
"Free" reserves Rs m2,419272,161 0.9%   
Net worth Rs m2,469272,530 0.9%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m4,605856,261 0.5%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.20.2 803.3%   
Return on assets %5.66.9 81.9%  
Return on equity %10.55.4 194.5%  
Return on capital %17.712.4 142.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30015,200 2.0%   
Fx outflow Rs m2,0154,889 41.2%   
Net fx Rs m-1,71510,312 -16.6%   
CASH FLOW
From Operations Rs m88-115,975 -0.1%  
From Investments Rs m-94-8,265 1.1%  
From Financial Activity Rs mNA107,525 0.0%  
Net Cashflow Rs m-6-16,650 0.0%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 15.7 26.6 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   12,856 93,274 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS